NCT06090617 (WHYSKI) is a clinical trial of Skin Biopsy in Hyperaldosteronism, sponsored by University Hospital Padova.

Who is sponsoring NCT06090617?

NCT06090617 is sponsored by University Hospital Padova.

What drugs are being tested in NCT06090617?

Interventions in NCT06090617: Skin Biopsy, Video-laparoscopic adrenalectomy.

What condition does NCT06090617 study?

NCT06090617 studies Hyperaldosteronism, Hypertension, Aldosterone-producing Adenoma, Aldosteronism, Aldosterone Disorder, Essential Hypertension, Bilateral Adrenal Hyperplasia, Conn Adenoma.

Is NCT06090617 still recruiting?

NCT06090617 is currently status unknown. Last updated 19 March 2024.

Last reviewed 2024-03-19 · How we verify

NCT06090617: WHYSKI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn

Status unknown Last updated 19 March 2024

What this trial tests

trial testing Skin Biopsy in Hyperaldosteronism in 35 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
1 April 2024

1 January 2025

Quick facts

Lead sponsor	University Hospital Padova
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	35
Start date	1 January 2021
Primary completion	1 April 2024
Estimated completion	1 January 2025
Sites	1 location across Italy

Drugs / interventions tested

Skin Biopsy
Video-laparoscopic adrenalectomy

Conditions studied

Hyperaldosteronism — all drugs for Hyperaldosteronism →
Hypertension — all drugs for Hypertension →
Aldosterone-producing Adenoma — all drugs for Aldosterone-producing Adenoma →
Aldosteronism — all drugs for Aldosteronism →

Sponsor

University Hospital Padova

Who can join

Adults 18 to 75, any sex, with Hyperaldosteronism or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

WHYSKI is a prospective within-patient observational clinical study designed to test the hypothesis that alterations of Na+, K+, water, and the lympho-angiogenetic transcription factor Tonicity Enhancing Binding Protein (TonEBP) mRNA take place in the interstitium of the skin compartment of patients with arterial hypertension due to primary aldosteronism in whom hypertension can be surgically cured.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Water and Electrolyte Content in Hypertension in the Skin (WHYSKI) in Primary Aldosteronism.
Torresan F, Rossi FB, Caputo I, Zanin S, et al · · 2024 · cited 3× · PMID 39355924 · DOI 10.1161/hypertensionaha.124.23700
Water and Electrolyte Content in Salt-Dependent HYpertension in the SKIn (WHYSKI): Effect of Surgical Cure of Primary Aldosteronism.
Torresan F, Rossi FB, Zanin S, Caputo I, et al · · 2024 · cited 1× · PMID 38123759 · DOI 10.1007/s40292-023-00614-0

Verify or expand the search:

Other trials of Skin Biopsy

Trials testing the same drug.

NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
NCT07011810 — Axatilimab for Sclerotic Chronic Graft-versus-Host Disease · Phase 2 · recruiting
NCT05515692 — Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease · EARLY_PHASE1 · withdrawn
NCT05739149 — A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers · NA · recruiting
NCT05993871 — Diabetic Small Fiber Neuropathy: Clinical, Electrophysiological and Neurosonographic Study · completed

Other recruiting trials for Hyperaldosteronism

Currently open trials in the same condition.

NCT07252284 — CHina Adrenal Venous saMPling InvestigatiON · recruiting
NCT06246357 — Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisoli · Phase 2 · recruiting
NCT05925569 — Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension · NA · active not recruiting
NCT07328230 — Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism · NA · recruiting
NCT04328181 — Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomo · NA · recruiting

Other University Hospital Padova trials

Trials by the same sponsor.

NCT07161752 — Applied Forces During Neonatal Ventilation With Different Face Masks · NA · completed
NCT06420115 — Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects · NA · recruiting
NCT06276413 — REgistRy BRAnch goRE EndopRosthEsis · not yet recruiting
NCT06254651 — Resuscitation Table Height for Face-mask Ventilation in Infants · NA · completed
NCT06161389 — Applied Forces During Neonatal Face Mask Ventilation With Different Face-mask Air Cushion Volumes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06090617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Padova
Last refreshed: 19 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06090617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing